New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
09:17 EDTMDCOThe Medicines Co. says sees Q1 net revenue $145M-$155M, consensus $157.55M
Says sees GAAP EPS loss (33c)-(24c) for Q1, may not compare to consensus of 27c. Says Q1 will be "burdened" by a number of one-time business circumstances. Sees FY13 worldwide net revenue growth 20%-22%, consensus $655.13M. Comments made on the Q4 earnings conference call.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTMDCOJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
May 26, 2015
10:39 EDTMDCOThe Medicines Co. says data show remodeling effect of MDCO-216 on HDL
Subscribe for More Information
May 20, 2015
06:55 EDTMDCOEagle Pharmaceuticals submits NDA for ready-to-use bivalirudin to FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use